key: cord-0030150-geopp3t7 authors: Ulhaq, Zulvikar Syambani; Soraya, Gita Vita; Dewi, Nadia Artha; Wulandari, Lely Retno title: The prevalence of anxiety symptoms and disorders among ophthalmic disease patients date: 2022-04-19 journal: Ther Adv Ophthalmol DOI: 10.1177/25158414221090100 sha: 1abce356879fe37e0cbfc5c459870aee6ddff5f9 doc_id: 30150 cord_uid: geopp3t7 BACKGROUND: Progressive and irreversible vision loss has been shown to place a patient at risk of mental health problems such as anxiety. However, the reported prevalence of anxiety symptoms and disorders among eye disease patients vary across studies. Thus, this study aims to clarify the estimated prevalence of anxiety symptoms and disorders among ophthalmic disease patients. METHODS: Relevant studies on the prevalence of anxiety symptoms and disorders among eye disease patients were collected through international databases, PubMed, Scopus, and Web of Science. A random-effects model was used to determine the pooled prevalence of anxiety symptoms and disorders among ophthalmic disease patients. RESULTS: The 95 included studies yielded a pooled prevalence of 31.2% patients with anxiety symptoms and 19.0% with anxiety disorders among subjects with ophthalmic disease. Pediatric patients were more anxious (58.6%) than adults (29%). Anxiety symptoms were most prevalent in uveitis (53.5%), followed by dry eye disease (DED, 37.2%), retinitis pigmentosa (RP, 36.5%), diabetic retinopathy (DR, 31.3%), glaucoma (30.7%), myopia (24.7%), age-related macular degeneration (AMD, 21.6%), and cataract (21.2%) patients. Anxiety disorders were most prevalent in thyroid eye disease (TED, 28.9%), followed by glaucoma (22.2%) and DED (11.4%). When compared with healthy controls, there was a twofold increase on the prevalence of anxiety symptoms (OR = 1.912, 95% CI 1.463–2.5, p < 0.001) and anxiety disorders (OR = 2.281, 95% CI 1.168–4.454, p = 0.016). CONCLUSION: Anxiety symptoms and disorders are common problems associated with ophthalmic disease patients. Thus, comprehensive and appropriate treatments are necessary for treating anxiety symptoms and disorders among ophthalmic disease patients. deterioration or limitations. As an example, vision loss is considered to be progressive and irreversible, placing the patient at increased risk of mental health problems which may negatively influence the individual's quality of life. 5 Several studies have shown the association between anxiety symptoms and ocular diseases. [6] [7] [8] However, the reported prevalence of anxiety symptoms and disorders in patients with ocular diseases remains highly varied, ranging from 2.4% to 78% 6,9 and 6.3% to 73%, respectively. 10, 11 Meanwhile, early identification and management of anxiety is crucial in eye disease cases, as acute emotional stress can result in sudden intraocular pressure (IOP) elevation in the glaucomatous eye and has been associated with severe ocular hypertension. 12 Due to the potential negative impact of poor mental health status on both the ophthalmic condition and general well-being of the patient, prompt identification and management of emotional and social factors correlated with anxiety should be taken into account in order to achieve optimal treatment. Indeed, patients with anxiety symptoms and disorders often experience significant impairment in functioning in global, social, occupational, and physical domains. 13 Thus, identification of the impairment profile for those suffering from anxiety is essential to understand the hurdles that treatment may need to overcome. Altogether, in order to quickly identify and manage anxiety issues in ophthalmic disease subjects, decision-makers require a representative estimate on the prevalence of said condition. Hence, this study aims to systematically review the reported prevalence of both anxiety disorders and symptoms in ophthalmic disease patients, and to provide a pooled prevalence of anxiety among the eye disease patients. This study was performed according to the instructions of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. 14 Criteria of studies included in this meta-analysis were: (1) observational studies that reported either anxiety symptoms or disorders among patients with eye disease; (2) anxiety symptoms/states and disorders examined based on a validated methods/tools and clinical diagnosis, respectively; (3) ophthalmic diseases diagnosed based on the judgment of qualified ophthalmologists or medical records according to the International Classification of Disease and Codes (ICD-11); and (4) both adult and pediatric age were included. Relevant studies were searched from electronic databases such as PubMed, Scopus, and Web of Science, utilizing the following keywords: anxiety, prevalence/incidence, and eye/ocular disease/ophthalmology until January 2022. Data extraction and quality assessment Data were extracted as follows: author, year of publication, study design, country, sample size, mean age of participants or otherwise indicated, type of disease, diagnostic method with its corresponding cutoff value, and the prevalence of anxiety disorders or symptoms. To assess the quality of the observational study, the Newcastle-Ottawa Scale (NOS) was applied. 15 The maximum score for each study is 9. Studies scoring less than 5 were judged to be at a high risk of bias. 16 Statistical analysis Prevalence estimates of anxiety symptoms and disorders were calculated from 95 studies. Heterogeneity was evaluated with the I 2 statistic, wherein I 2 values more than 50% indicated substantial heterogeneity. If heterogeneity existed, the random-effects model was then used; otherwise, the fixed-effects model was applied. Secondary analysis was used to evaluate the prevalence of anxiety symptoms and disorders among patients with ophthalmic disease relative to healthy subjects. A funnel plot and Begg's test were used to investigate the publication bias if the pooled effect size consisted of 10 or more studies. [17] [18] [19] [20] [21] [22] Metaanalysis was performed utilizing Open Meta-Analyst software package. 23 The value of 0.05 was indicative of statistical significance. Ninety-five studies were included in this metaanalysis, [6] [7] [8] [9] [10] [11] among which 81 evaluated anxiety symptoms while 14 evaluated anxiety disorders among patients with ophthalmic disease (Figure 1 ). The characteristics of the included studies are shown in Table 1 . The prevalence of anxiety symptoms and disorders among ophthalmic disease patients ranged from 2.4% to 95.87% and 6.5% to 77.5%, respectively. The random-effect model was used because heterogeneity existed (I 2 > 50%). The overall pooled prevalences of Figure 4 (a))], followed by patients with dry eye disease (DED) (37.2%, 95% CI, 17.4%-40.5%, p < 0.001, Figure 4 (b)), retinitis pigmentosa (RP) (36.5%, 95% CI, 19.8%-54.6%, p < 0.001, Figure 4 (c)), diabetic retinopathy (DR) (31.3%, 95% CI, 13.5%-49.1%, p < 0.001, Figure 4 Figure 5 (a))], myopia (24.7%, 95% CI, 20%-29.4%, p < 0.001, Figure 5 (b)), agerelated macular degeneration [AMD, 21.6%, 95% CI, 12.5%-30.7%, p < 0.001, Figure 5 (c); patients with wet AMD had a higher prevalence of anxiety symptoms (34.3%, 95% CI, 16.6%-52%, p < 0.001) than those with any type of AMD (15.3%, 95% CI, 8.3%-22.3%, p < 0.001, Figure 5 (c))], and cataract (21.2%, 95% CI, 7.8-34.6%, p = 0.002, Figure 5(d) ). For anxiety disorders, the highest prevalence was detected in patients with thyroid eye disease (TED) (28.9%, 95% CI, 21.8%-36%, p < 0.001, Figure 6 (a)), followed by patients with glaucoma (22.2%. 95% CI, 11.7%-32.6%, p < 0.001, Figure 6 (b)) and DED (11.4%. 95% CI, 10.5%-12.2%, p < 0.001, Figure 6(b) ). For the secondary analysis, 22 and 8 studies evaluating anxiety symptoms and disorders among patients with the ophthalmic disease were analyzed. The overall results indicated that relative to healthy controls, patients with ocular disease exhibit nearly a twofold increase of experiencing anxiety symptoms (OR = 1.912, 95% CI 1.463-2.5, p < 0.001, Figure 7 (a)), of which patients with DED had slightly higher anxiety symptoms (OR = 2.19, 95% CI 1.411-3.399, p < 0.001, Figure 7 (b)) than those with glaucoma (OR = 1.822, 95% CI 1.058-3.135, p = 0.03, Figure 7 (c)), but these findings were not observed in patients with myopia nor AMD (Supplemental Figure 1A and B). In line, the risk of developing anxiety disorders among ophthalmic disease patients was two times higher than in control subjects (OR = 2.281, 95% CI 1.168-4.454, p = 0.016, Figure 8 ). The funnel plot generated from 22 studies was symmetrical (Supplemental Figure 1 C) with the Begg's test (p = 0.108), indicating no evidence of publication bias. This study showed that the prevalence of anxiety symptoms and disorders among patients with ophthalmic disease were relatively higher than that reported in the general population. 1, 99 We also found that anxiety symptoms and disorders were two times more prevalent among patients with ophthalmic disease than control subjects. Based on the type of eye disease, the highest prevalence of anxiety symptoms was found in patients with uveitis, followed by DED, RP, DR, glaucoma, myopia, AMD, and cataract. Similarly, anxiety disorders were also commonly occurred in patients with glaucoma and DED in addition to TED. It is interesting to note that pediatric patients with ocular disease tended to have a higher prevalence of anxiety symptoms than adults. This is because children may have low coping strategies against potentially 10 journals.sagepub.com/home/oed journals.sagepub.com/home/oed 11 stressful situations or alternatively, both primary and secondary control coping may not fully develop in early childhood due to a lack of concrete operational cognitive capacities. 100 Although most of the studies showed low-risk of bias, heterogeneity was observed across the studies. This is possibly due to a variety of detection methods/ assessment tools and its cutoff value. Our study suggests that a higher prevalence of anxiety symptoms was frequently occurred in patients with chronic eye disease (in our study, we reported such as Behçet uveitis, TED, glaucoma, RP, DR, macular degeneration, uncorrected refractive error, and cataract). More than 50% of patients with Behçet uveitis had experience anxiety symptoms. Indeed, depression and anxiety are consistently observed disorders in Behçet's disease (BD) individuals across studies. 101 It is notable that in 2017, a meta-analysis performed by Wan et al. 68 indicates that DED is associated with nearly a three times increase in the prevalence of anxiety. Recently, Basilious et al. 102 indicated possible interrelationships between DED severity with anxiety symptoms. In agreement with this finding, Zhang et al. 42 demonstrated that glaucoma patients exhibit a 10-fold increase in the risk of developing anxiety disorders. In addition, for the first time, we have shown a higher prevalence of anxiety symptoms in PACG than POAG subjects. This is possibly because relative to POAG, PACG carries a threefold increased risk of severe bilateral visual impairment. 103 In parallel, Dawson et al. 104 showed that the prevalence estimate of anxiety symptoms in people with AMD ranges from 9.6% to 30.1%, and interestingly, we found that patients with wet AMD had slightly higher anxiety symptoms than previously reported. 104 Although both glaucoma and AMD are considered slow-progressing eye diseases, acute onset of vision loss often occurs in wet AMD. Therefore, patients usually seek a rapid referral and treatment. On the other hand, the lives of people with glaucoma are largely unaffected while the disease progresses silently, which may have a long-term negative impact on their quality of life. 105 Thus, according to our findings, it is possible to hypothesize that the chronicity of glaucoma may be closely associated with the development of anxiety symptoms and disorders. Patients with TED often have a problem with the disfigurement of the eye. This can change the appearance of the eyes and lead to affected individuals looking tired all the time. 106 These cosmetic issues can have a significant impact on emotional well-being and may be correlated with the development of anxiety disorders, because patients may face exclusion more often due to their facial appearance. Together, our study suggests that anxiety symptoms and disorders are common problems associated in patients with ophthalmic disease. Anxiety symptoms and disorders that occur in ophthalmic disease patients may be due to several factors, such as a feeling of hopelessness and failing to cope, as a consequence of the untreatable and unpredictable losses of the visual field 107 and losing of the driving license. 108 The anxiety may 12 journals.sagepub.com/home/oed also be elicited by socioeconomic aspects, including increased costs from doctor and hospital visits, medications, and health care. 109, 110 From a biochemical standpoint, low serotonin levels (5-HT) have been associated with anxious behavior. 111 Indeed, the reduction of serum 5-HT levels is observed in patients with glaucoma and chronic central serous chorioretinopathy. 112, 113 Interestingly, the administration of selective serotonin reuptake inhibitors (SSRIs) as well as anti-anxiety has been shown to not only improve anxiety symptoms but also suppressed the intraocular pressure (IOP) in glaucomatous patients, 114 thereby implying that 5-HT may involve in glaucoma pathogenesis. Nevertheless, comprehensive and appropriate treatments are necessary for treating anxiety disorders among ophthalmic disease patients, which may help to reduce the cost of treatment. Moreover, cooperation between ophthalmologists and psychiatrists is essential to support complete eye treatment and to improve mental health conditions. One of the strengths of this study is that it represents a comprehensive and updated evaluation on the prevalence of anxiety symptoms and disorders in all patients with ocular disease, while a previous study by Zheng et al. 115 only specifically evaluated depression and depressive symptoms. Moreover, in the previous studies, 68,115 they combine both symptoms and disorders as a single entity, but in fact, anxiety symptoms and disorders are two different entities. In addition, the strengths of the study included the in-depth analysis of anxiety symptoms in the pediatric group, which was not previously examined. Some limitations should be noted when interpreting these findings. (1) Because anxiety is often comorbid with depression, the inclusion of studies that report a mixed prevalence of anxiety and depression may have influenced the prevalence estimate in this study. (2) Because the instruments for examining the anxiety symptoms or states are not uniform, this possibly contributes to the observed heterogeneity in this metaanalysis. (3) The uneven number of studies on glaucoma, DED, and AMD could be the other possible source of bias. (4) Because most of the included studies were designed as cross-sectional studies, the causal relationship between anxiety symptoms/disorders and ocular diseases can not be determined. (5) Included studies in the pediatric population are limited, thus the current finding may not be precise and further studies are still required. In conclusion, our study implies that anxiety symptoms and disorders are common among ophthalmic disease patients. Therefore, a comprehensive and collaborative approach is essential 116, 117 to quickly identify and effectively care for ophthalmic Global prevalence of anxiety disorders: a systematic review and meta-regression Anxiety disorders: a review of current literature Treatment of anxiety disorders Epidemiology of anxiety disorders in the 21st century Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine Prevalence of cognitive impairment, depression, and anxiety symptoms among older adults with glaucoma Depressive symptoms and quality of life in age-related macular degeneration based on Korea National Health and Nutrition Examination Survey (KNHANES) Association between diabetes-related eye complications and symptoms of anxiety and depression Evaluating the quality of life of glaucoma patients using the State-Trait Anxiety Inventory Figure 8. Forest plot of the pooled prevalence of anxiety disorders in patients with ophthalmic disease and control subjects Visual impairment and health-related quality of life among elderly adults with age-related eye diseases Mood and anxiety disorders in women with treated hyperthyroidism and ophthalmopathy caused by Graves' disease Acute emotional stress as a trigger for intraocular pressure elevation in Glaucoma Anxiety symptoms and functional impairment: a systematic review of the correlation between the two measures Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement Exposure to second-hand smoke and the risk of tuberculosis in children and adults: a systematic review and meta-analysis of 18 observational studies quality improvement interventions to address health disparities) Estrogen receptor beta (ESR2) gene polymorphism and susceptibility to dementia Inflammation-related gene polymorphisms associated with Parkinson's disease: an updated meta-analysis Recurrent positive SARS-CoV-2 RNA tests in recovered and discharged patients The association between genetic polymorphisms in estrogen receptor genes and the risk of ocular disease: a meta-analysis The association of estrogen-signaling pathways and susceptibility to open-angle glaucoma The prevalence of ophthalmic manifestations in COVID-19 and the diagnostic value of ocular tissue/fluid Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data Anxiety, depression, and quality of life in Turkish patients with glaucoma Clinically relevant symptoms of anxiety and depression in low-vision community-living older adults Prevalence of depression, anxiety, adjustment disorders, and somatoform disorders in patients with age-related macular degeneration in Germany Impact of retinitis pigmentosa on quality of life, mental health, and employment among young adults Vision and hearing impairments are associated with depressive-anxiety syndrome in Italian elderly Ocular surface health in Shanghai University students: a cross-sectional study Usefulness of the Hospital Anxiety and Depression Scale for screening for psychiatric morbidity in Chinese patients with Graves' ophthalmopathy Risk factors for anxiety and depression in patients diagnosed with glaucoma at the Philippine General Hospital Illness uncertainty, anxiety and depression in Chinese patients with glaucoma or cataract Validity of EuroQOL-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population Depression and anxiety in patients with glaucoma or glaucoma suspect Quantitative analyses of factors related to anxiety and depression in patients with retinitis pigmentosa The role of control in depression, anxiety, and life satisfaction among visually impaired older adults Depressive symptoms and quality of life in people with age-related macular degeneration Screening for depression and anxiety in patients with active uveitis Dry eye disease and depression-anxiety-stress: a hospitalbased case control study in Turkey Assessment of anxiety and depression in primary open angle glaucoma patients (a study of 100 cases) Dry eye disease in patients with depressive and anxiety disorders in Shanghai The association between glaucoma, anxiety, and depression in a large population Anxiety and depression prevalence rates in age-related macular degeneration The differences in level of trait anxiety among girls and boys aged 13-17 years with myopia and emmetropia Watchful waiting for subthreshold depression and anxiety in visually impaired older adults Prevalence of depression and anxiety among participants with glaucoma in a population-based cohort study: the Gutenberg Health Study Vision-related quality of life and psychological status in Chinese women with Sjogren's syndrome dry eye: a casecontrol study Depression, anxiety, and disturbed sleep in glaucoma Depression and anxiety in patients with pseudoexfoliative glaucoma Depression and anxiety in visually impaired older people The psychological well-being and appearance concerns of patients presenting with ptosis Co-morbidity of depression and anxiety in common age-related eye diseases: a populationbased study of 662 adults Anxiety and depression are more prevalent in primary angle closure glaucoma than in primary open-angle glaucoma Anxiety and depression in patients with dry eye syndrome Assessment of depression, anxiety, and quality of life in Singaporean patients with glaucoma Dry eyerelated visual blurring and irritative symptoms and their association with depression and anxiety in eye clinic patients High prevalence of anxiety and depression in patients with primary open-angle glaucoma Depression, stress, quality of life, and dry eye disease in Korean women: a population-based study High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors Prevalence of mental health illness among patients with adult-onset strabismus Major depressive and anxiety disorders in visually impaired older adults The association between dry eye disease and depression and anxiety in a large populationbased study Vision-related quality of life in glaucoma patients and its correlations with psychological disturbances and visual function indices Anxiety and depression in Chinese patients with glaucoma: sociodemographic, clinical, and self-reported correlates Depression and anxiety in dry eye disease: a systematic review and meta-analysis Anxiety and depression of glaucoma patients and the influencing factor Influencing factors of anxiety and depression among patients with primary open-angle glaucoma before and after surgical interventions Health-related quality of life and anxiety associated with childhood intermittent exotropia before and after surgical correction Assessment of quality of life, mental health and ocular morbidity in children from schools for the blind in North-East India Prevalence of anxiety and depression in patients with primary glaucoma in Western India Prevalence of depressive and anxiety disorders in patients with glaucoma: a cross-sectional study Factors associated with depression and anxiety among glaucoma patients in a tertiary hospital South-East Nigeria The effect of anxiety and depression on progression of glaucoma Optical quality assessed by optical quality analysis system in Chinese primary open-angle glaucoma patients and its correlations with psychological disturbances and vision-related quality of life Prevalence and new onset of depression and anxiety among participants with AMD in a Assessment of vision-related quality of life and depression and anxiety rates in patients with neovascular age-related macular degeneration Experience of anti-VEGF treatment and clinical levels of depression and anxiety in patients with wet age-related macular degeneration Is perceived social support more important than visual acuity for clinical depression and anxiety in patients with age-related macular degeneration and diabetic retinopathy Association between sleep quality, mood status, and ocular surface characteristics in patients with dry eye disease The relationship of dry eye disease with depression and anxiety: a naturalistic observational study The correlation between dry eyes, anxiety and depression: the sicca, anxiety and depression study The effect of vision-related quality of life on depression and anxiety in patients with behçet uveitis Quality of life and psychological aspects in patients with visual impairment secondary to uveitis: a clinical study in a tertiary care hospital in Brazil Anxiety and depression in patients wearing prosthetic eyes Association between self-care agency and depression and anxiety in patients with diabetic retinopathy Quality-of-life and psychosocial aspects in patients with ocular toxoplasmosis: a clinical study in a tertiary care hospital in Brazil Quality of life and treatment-related burden during ocular proton therapy: a prospective trial of 131 patients with uveal melanoma Vision-related quality of life, anxiety and depression in congolese patients with polypoidal choroidal vasculopathy Longitudinal associations of self-reported vision impairment with symptoms of anxiety and depression among older adults in the United States Impact of anxiety and depression on progression to glaucoma among glaucoma suspects Pain in dry-eye patients without corresponding clinical signs -a retrospective analysis The association between mental health disorders and noninfectious scleritis: a prevalence study and review of the literature Quality of life in patients with chronic thyroid eye disease in the United States Physician-perceived impact of thyroid eye disease on patient quality of life in the United States Psychiatric evaluation in patients with central serous chorioretinopathy in Asian Indians Prevalence and course of subthreshold anxiety disorder in the general population: a three-year follow-up study Coping with stress among preschool children and associations with anxiety level and controllability of situations Depression and anxiety in patients with Behçet's disease compared with that in patients with psoriasis Dry eye disease and psychiatric disorders: a systematic review and meta-analysis Primary angle closure glaucoma: what we know and what we don't know The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data Quality of life in glaucoma and three other chronic diseases: a systematic literature review Minimally invasive surgery for thyroid eye disease Anxiety and depression in patients with advanced macular degeneration: current perspectives Changing visual standards in driving: but a high proportion of eye patients still drive illegally Health care costs associated with depressive and anxiety disorders in primary care A review of the diagnosis, pharmacologic treatment, and economic aspects of anxiety disorders Brain aromatase modulates serotonergic neuron by regulating serotonin levels in zebrafish embryos and larvae Reduced blood serotonin levels in chronic central serous chorioretinopathy Serotonin levels in aqueous humor of patients with primary open-angle glaucoma The risk of glaucoma and serotonergic antidepressants: a systematic review and meta-analysis The prevalence of depression and depressive symptoms among eye disease patients: a systematic review and metaanalysis Autoimmune dry eye without significant ocular surface co-morbidities and mental health Anxiety and depression in inflammatory eye disease: exploring the potential impact of topical treatment frequency as a putative psychometric item The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The authors received no financial support for the research, authorship, and/or publication of this article. For this type of study (meta-analysis), ethical committee approval is not required.